Dana-Farber Cancer - phosphoinositide 3 (PI3) kinase
Recent post by Lab Man (Stock twits).
$KZIA Lewis Cantley is soon to join Dana Farber. It is said that his move from Weill Cornell, to team with Tom Roberts and Jean Zhao from DF, will create a dream team approach for the development of phosphatidylinositol inhibitors. Dr. Roberts is a Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and serves as Co-Chairman for the Department of Cancer Biology at Dana-Farber Cancer Institute. The first definitive studies on phosphoinositide 3 (PI3) kinase were done by the Roberts lab in collaboration with the lab of Lewis Cantley. Dr Roberts has studied PI3K in detail, collaborating with Jean Zhao and Priscilla Brastianos, to generate conditional knockout mice for the commonly expressed catalytic subunits of PI3K. The end goal of these studies, determining which isoforms to target in specific cancers. In recent times, KZIA has collaborated in a total of 7 clinical trials with Harvard Medical and Weill Cornell.
Exciting times ahead for paxalisib and maybe a new trial in combination with other drugs.
Regards.
KZA Price at posting:
$1.43 Sentiment: Buy Disclosure: Held
